Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 3, keine Gesamtzahl für „Trulicity“
Suchtreffer
Begriffe & Kennungen
Trulicity · 4.8 · Immunogenicity In registration studies, treatment with dulaglutide was associated with a 1.6 % incidence of tr
Eintrag öffnenTrulicity · 4.8 · In a phase 3 study through to week 52, when dulaglutide 1.5 mg, 3 mg and 4.5 mg were used in combination with
Eintrag öffnenTrulicity · 4.8 · In a phase 3 study with 1.5 mg, 3 mg and 4.5 mg dulaglutide doses respectively, cumulative reporting of gastro
Eintrag öffnenTrulicity · 4.8 · In a phase 3 study with 1.5 mg, 3 mg and 4.5 mg dulaglutide doses, the incidence of discontinuation due to adv
Eintrag öffnenTrulicity · 4.8 · In a phase 3 study with 1.5 mg, 3 mg and 4.5 mg dulaglutide doses, the incidence of first-degree AV block was
Eintrag öffnenTrulicity · 4.8 · In a phase 3 study with 1.5 mg, 3 mg and 4.5 mg dulaglutide doses, the incidence of sinus tachycardia, with a
Eintrag öffnenTrulicity · 4.8 · In the completed phase 2 and phase 3 studies to support the initial registration of dulaglutide 0.75 mg and 1.
Eintrag öffnenTrulicity · 4.8 · Injection site reactions Injection site adverse events were reported in 1.9 % of patients receiving dulaglutid
Eintrag öffnenTrulicity · 4.8 · Paediatric population The safety profile in paediatric patients aged 10 years and above treated with dulagluti
Eintrag öffnenTrulicity · 4.8 · Pancreatic enzymes Dulaglutide is associated with mean increases from baseline in pancreatic enzymes (lipase a
Eintrag öffnenTrulicity · 4.8 · Reporting of suspected adverse reactions
Eintrag öffnenTrulicity · 4.8 · Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows con
Eintrag öffnenTrulicity · 4.8 · Summary of safety profile
Eintrag öffnenTrulicity · 4.8 · System organ Very common Common Uncommon Rare Not class known
Eintrag öffnenTrulicity · 4.8 · Table 1. The frequency of adverse reactions of dulaglutide
Eintrag öffnenTrulicity · 4.8 · Tabulated list of adverse reactions
Eintrag öffnenTrulicity · 4.8 · The following adverse reactions have been identified based on evaluation of the full duration of the phase 2 a
Eintrag öffnenTrulicity · 4.8 · The immunogenicity profile in paediatric patients treated with dulaglutide is consistent with that described a
Eintrag öffnenTrulicity · 4.8 · The incidence of documented symptomatic hypoglycaemia when dulaglutide 1.5 mg was used in combination with ins
Eintrag öffnenTrulicity · 4.8 · The incidences of documented symptomatic hypoglycaemia when dulaglutide 0.75 mg and 1.5 mg, respectively, were
Eintrag öffnen